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1 Inflammmatory bowel disease (IBD) is characterized by oxidative and nitrosative stress, leucocyte
infiltration and upregulation of proinflammatory cytokines. In this study, we have investigated the
protective effects of curcumin, an anti-inflammatory and antioxidant food derivative, on 2,4,6-
trinitrobenzene sulphonic acid-induced colitis in mice, a model for IBD.
2 Intestinal lesions (judged by macroscopic and histological score) were associated with neutrophil
infiltration (measured as increase in myeloperoxidase activity in the mucosa), increased serine protease
activity (may be involved in the degradation of colonic tissue) and high levels of malondialdehyde (an
indicator of lipid peroxidation).
3 Dose – response studies revealed that pretreatment of mice with curcumin (50mg kg1 daily i.g. for
10 days) significantly ameliorated the appearance of diarrhoea and the disruption of colonic
architecture. Higher doses (100 and 300mg kg1) had comparable effects.
4 In curcumin-pretreated mice, there was a significant reduction in the degree of both neutrophil
infiltration (measured as decrease in myeloperoxidase activity) and lipid peroxidation (measured as
decrease in malondialdehyde activity) in the inflamed colon as well as decreased serine protease
activity.
5 Curcumin also reduced the levels of nitric oxide (NO) and O2
 associated with the favourable
expression of Th1 and Th2 cytokines and inducible NO synthase. Consistent with these observations,
nuclear factor-kB activation in colonic mucosa was suppressed in the curcumin-treated mice.
6 These findings suggest that curcumin or diferuloylmethane, a major component of the food flavour
turmeric, exerts beneficial effects in experimental colitis and may, therefore, be useful in the treatment
of IBD.
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Introduction
Inflammatory bowel disease (IBD), identified and diagnosed
by a set of clinical, endoscopic, and histological features
(Kirsner & Shorter, 1988), is of still unknown aetiology.
Treating IBD while limiting drug-induced toxicity is a
continuous challenge. 5-Aminosalicyclic acid and salazosul-
phapyridine are the drugs of choice for current medical
treatment. Corticosteroids, azathioprine, mercaptopurines and
cyclosporine are used in more severe forms of the disease
(Hanauer, 1996). Owing to the lack of specific, curative
treatments with limited toxicity, there is a pressing need for
developing effective therapeutic approaches. Various models
of IBD have been found to be associated with an over-
production of nitric oxide (NO) because of the expression of
the inducible isoform of NO synthase (iNOS) (Nathan, 1996).
Increased luminal activities of NO have also been detected in
ulcerative colitis (UC) (Lundberg et al., 1994) and in the
colonic lavage fluid in different animal models of IBD (Feretti
et al., 1997; Gunawardana et al., 1997). Excessive production
of NO in chronic colitis may be detrimental to the integrity of
the colonic mucosa (McKenzie et al., 1996). In accordance
with this information NO-related treatments serve as a
promising pharmacological approach in the treatment of these
disease states (Neilly et al., 1995; Rachmilewitz et al., 1995a).
Interventions, which reduce the generation or the effects of
reactive nitrogen, exert beneficial effects in a variety of models
of inflammation, including the trinitrobenzene sulphonic acid-
induced colitis used here (Miller et al., 1993; Hogaboam et al.,
1995; Neilly et al., 1996). In contrast to these findings,
however, it has been reported that genetic ablation of iNOS
activation may exacerbate intestinal inflammation induced by
intraluminal administration of acetic acid in mice (McCafferty
et al., 1997). Other experimental studies have shown that only
slight pharmacological inhibition of NO formation reduced
colonic lesions, while a complete abolition of NO synthesis
resulted in increased mucosal damage (Pfeiffer & Qiu, 1995).
The critical contribution of iNOS to the pathogenesis of IBD,
therefore, has not been clearly delineated.
The use of medicinal plants or their active components is
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of various inflammatory disorders among patients unrespon-
sive to or unwilling to take standard medicines. Among these
alternative approaches is the use of food derivatives, which
have the advantage of being relatively nontoxic. However,
limited scientific evidence regarding the effectiveness of these
natural derivatives, in conjunction with a lack of mechanistic
understanding of their actions has prevented their incorpora-
tion into the mainstream of medical care. During the last
decade, a large number of dietary components have been
evaluated as potential chemopreventive agents (Sharma et al.,
1994). Turmeric, the powdered rhizome of the medicinal plant,
Curcuma longa Linn, is widely used as a food flavouring and
colouring agent in the Asian diet. Its yellow colour is imparted
by curcumin (diferuloylmethane), a polyphenolic pigment
(Cooper et al., 1994). Curcumin has a long history of medicinal
use in India and Southeast Asia and is known to exhibit a
variety of pharmacological effects including anti-inflamma-
tory, antitumour, anti-HIV and anti-infectious activities
(Mazumder et al., 1996; Allen et al., 1998; Chan et al., 1998;
Vlietinck et al., 1998). It is under preclinical evaluation for
drug development of cancer prevention and anti-inflammation
(Gescher et al., 1998). Interest in curcumin and its promising
medicinal value is growing, especially since it does not appear
to be significantly toxic (Ammon & Wahl, 1991) and exhibits
marked antioxidant and anti-inflammatory properties. Thus,
curcumin scavenges active oxygen species including super-
oxide, hydroxyl radical and NO (Sreejayan & Rao, 1997). It
decreases the 12-O-tetradecanoylphorbol-13-acetate-induced
expression of c-jun, c-fos and c-myc proto-oncogenes (Kakar
& Roy, 1994), suppresses activation of nuclear factor-kB (NF-
kB) (Singh & Aggarwal, 1995) and elevates the activities of
detoxification enzymes of xenobiotic metabolism, such as
glutathione transferases and NAD(P)H : quinone reductase
(Arbiser et al., 1998).
Of the several animal models of intestinal inflammation, the
well-characterized haptene reagent 2,4,6-trinitrobenzene sul-
phonic acid (TNBS)-induced colitis resembles human IBD in
terms of its various histological features including infiltration
of colonic mucosa by neutrophils and macrophages and
increased production of inflammatory mediators including T-
helper 1 profile of cytokines (Parronchi et al., 1997). More-
over, various experimental trials using antibodies to IL-12, IL-
4 gene transfer, and antisense oligonucleotides against NF-kB
have indicated that the TNBS-induced colitis model is useful to
test new therapeutic strategies for human (Neurath et al., 1996;
Hogaboam et al., 1997; Fuss et al., 1999). Since food flavour
turmeric-derived curcumin is a major source of dietary
flavonoid having antioxidative and antinitrosative effects and
since IBD is associated with a marked upregulation of NO, it
was thought worthwhile to investigate the effects of curcumin
on the inflammatory response (colitis) caused by intracolonic
administration of TNBS.
Methods
Animals and reagents
Female BALB/c mice weighing 25 – 30 g (obtained from
National Institute of Nutrition, Hyderabad, India) were used
for the experiments. Mice were housed under normal
laboratory conditions, that is, at 21 – 241C and 40 – 60%
relative humidity, under a 12 h light/dark cycle with free access
to standard rodent food and water. Curcumin was purchased
from Sigma Chemical Co., St Louis, MO, U.S.A. For the oral
administration experiments, curcumin was emulsified in 2.5%
carboxymethyl cellulose and various dosages ranging from
25mg to 300mgkg1 were administered by gavage.
Experimental colitis
Colitis was induced in mice by intrarectal administration of
0.1ml of TNBS (60mgml1 in 30% ethanol), through a
trochar needle approximately 3 – 4 cm proximal to the anus
according to the model described earlier (Neurath et al., 1995).
Control mice received 30% ethanol in phosphate-buffered
saline (PBS) using the same technique. In the treated group
of animals, curcumin was given daily i.g. (25mg to
300mgkg1 day1) for 10 days before subjecting the mice to
TNBS-induced colitis and same dose of curcumin was
continued till the mice were killed 8 days after the induction
of colitis.
Macroscopic assessment of severity of colitis
Mice were killed by cervical dislocation, the colon excised,
opened longitudinally, and washed in saline. Macroscopic
damage was assessed by the scoring system of Wallace &
Keenan (1990), which takes into account the area of
inflammation and the presence and absence of ulcers. The
criteria for assessing macroscopic damage were based on a
semiquantitative scoring system where features were graded as
follows: 0, no ulcer, no inflammation; 1, no ulcer, local
hyperaemia; 2, ulceration without hyperaemia; 3, ulceration
and inflammation at one site only; 4, two or more sites of
ulceration and inflammation; 5, ulceration extending more
than 2 cm. After macroscopic observation, samples of colonic
tissue were subsequently excised for microscopic observation
of damage, measurement of myeloperoxidase activity, mal-
ondialdehyde, NO and O2
 production, and mRNA expression
of cytokines and iNOS.
Microscopic assessment of colitis
The colon was fixed in 10% formalin in PBS for 1 week and
the samples were then dehydrated in graded ethanol and
embedded in paraffin. Thereafter, 7 mm sections were depar-
affinized with xylene, stained with haematoxylin – eosin and
examined in a Leitz Ortholux microscope. Histologic changes
were graded semiquantitatively from 0 to 4 according to
previously described criteria (Neurath et al., 1995) as follows:
0, no leucocyte infiltration; 1, low level of leucocyte infiltra-
tion; 2, moderate level of leucocyte infiltration; 3, high
vascular density and thickening of colon wall; and 4,
transmural leucocyte infiltration, loss of goblet cells, high
vascular density and thickening of the colon wall.
Assessment of NO production
Tissues from the proximal third of the colon were homo-
genized in 40mM HEPES containing 320mM sucrose. Nitri-
te+nitrate production, an indicator of NO synthesis, was
measured in the supernatant (10,000 g for 20min at 41C)
according to Zingarelli et al. (1997). Nitrate in the supernatant
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was reduced to nitrite by incubation with nitrate reductase
(670mUml1) and NADPH (160mM) at room temperature
for 3 h. A measure of 100ml of the sample was then mixed with
an equal volume of Griess reagent (1% sulphanilamide and
0.1% N-(1-napthyl)-ethylenediamine dihydrochloride in 5%
H3PO4) and incubated at room temperature for 10min.
Absorbance at 540 nm was then measured. The amount of
nitrite released was quantified by comparison with sodium
nitrite as standard.
Estimation of O2

Superoxide production was measured as described previously
(Markert et al., 1984). In brief, 106 extravasated neutro-
phils were incubated for 30min at 371C in the presence of
2 mgml1 PMA, 1mgml1 cytochrome c, 30mgml1 catalase,
7100 mgml1 superoxide dismutase in D-glucose PBS. The
cells were then removed by centrifugation and the absorbance
of reduced cytochrome c measured at 550 nm.
Myeloperoxidase activity
Myeloperoxidase is an enzyme found in cells of myeloid origin,
and has been used extensively as a biochemical marker of
granulocyte (mainly neutrophil) infiltration into gastrointest-
inal tissues (Morris et al., 1989). Samples of distal colon were
homogenized in 10mM potassium phosphate buffer, pH 7.0
containing 0.5% hexadecyltrimethylammonium bromide and
centrifuged for 30min at 20,000 g at 41C. An aliquot of the
supernatant was then allowed to react with a solution of
1.6mM tetramethyl benzidine and 0.1mM H2O2. The rate of
change in absorbance was measured spectrophotometrically at
650 nm. One unit of myeloperoxidase activity was defined as
that degrading 1mmol of H2O2 per min at 371C and was
expressed as units per milligram of tissue sampled (Umg1
tissue).
Malondialdehyde measurement
Malondialdehyde levels in the colon were determined as an
indicator of lipid peroxidation (Ohkawa et al., 1979). The
tissue was homogenized in 1.15% KCl solution. A measure of
0.1ml of the homogenate was then added to a reaction mixture
containing 0.2 ml of 8.1% SDS, 1.5ml of 20% acetic acid,
1.5ml of 0.8% thiobarbituric acid and 0.7ml of distilled water.
Samples were boiled for 1 h at 951C and centrifuged at
3000 g for 10min. The absorbance of the supernatant was
measured by spectrophotometry at 650 nm.
Analysis of protease activity
A small piece of colon tissue from the centre of the ulcer was
homogenized for 10 s in cold PBS. The homogenate was
centrifuged (14,000 g for 5min at 41C) and the supernatant
was analysed for protease activity on gelatin zymograms
according to Hawkins et al. (1997). In short, 12% SDS –
polyacrylamide gels were prepared containing 0.1% gelatin.
An equal amount of protein from each sample (10 – 25mg) was
applied to the gel in standard SDS-gel loading buffer contain-
ing 0.1% SDS but lacking b-mercaptoethanol and samples
were not boiled prior to loading. After electrophoresis, gels
were soaked in 2% Triton X-100 in distilled water with
shaking for 15min. Gels were then incubated in 50mM Tris-
HCl, pH 8.0 containing 1mM CaCl2 for 12 h at 371C, stained
in amido black and subsequently destained. Protease activity
shows up as clear bands (indicative of cleavage of the gelatin
substrate) on a blue background.
RT – PCR analysis of cytokines and iNOS mRNA
RT – PCR was performed in colon tissue samples from mice 4
days post-TNBS to determine the cytokine profile of mRNA
for IFN-g, IL-12 p40, IL-4, iNOS and b-actin. Reverse
transcription of 1 mg of RNA was performed according to
the manufacturer’s protocol for the Superscript One-Step
RT – PCR system (Life Technologies, Grand Island, NY,
U.S.A.). The primers for all these genes have been published
(Kawakami et al., 1997). After the appropriate number of PCR
cycles, the amplified cDNA was separated by 2% agarose gel
electrophoresis and visualized by ethidium bromide staining.
Electrophoretic mobility shift assay
The nuclear extracts were prepared from excised colon
according to the method of Yang et al. (1998). For
electrophoretic mobility shift assay, each 10mg of nuclear
extracts were preincubated with 1mg of poly(dI-dC) in a
binding buffer (25mM HEPES, pH 7.9, 0.5mM EDTA, 0.5mM
dithiothreitol, 1% Nonidet P-40, 5% glycerol and 50mM
NaCl) for 10min at room temperature. As a control, a
50-fold molar excess of unlabelled NF-kB competitor
oligonucleotide was added. After preincubation, 0.5 ng
of 32P end-labelled NF-kB oligonucleotide probe (50-
CGGGGACTTTCCGCTGGGGACTTTCCGCTTGAGCT-
30) was added to the reaction mixture and incubated for
30min. The DNA – protein complex was then electrophoresed
on 4.5% nondenaturing polyacrylamide gels in 0.5X TBE
buffer (0.0445M Tris, 0.0445M borate, 0.001M EDTA).
Statistical analysis
Results are expressed as mean7s.d. of n observations. We
used analysis of variance to determine the statistical signifi-
cance of intergroup comparisons. Po0.05 was considered to
be statistically significant. Macroscopic and microscopic scores
for colonic erosions for the curcumin-pretreated groups were
compared against those for the TNBS-treated group with a
two-sided Wilcoxon’s rank-sum test.
Results
Macroscopic and histological evaluation
Intracolonic administration of TNBS/ethanol resulted in
extensive haemorrhagic and ulcerative damage to the distal
colon as observed up to 8 days. Macroscopic examination of
the distal colon and rectum from TNBS-treated mice revealed
the presence of multiple mucosal erosions and ulcerations. The
caecum, colon and rectum showed evidence of mucosal
congestion, erosions and haemorrhagic ulcerations evaluated
to a peak at 4 days as shown in the damage score (Figure 1).
The histological features included a transmural necrosis and
oedema and a diffuse leucocyte cellular infiltrate in the
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submucosa (Figure 2b). Control group gave rise to a very mild
early damage of the colon. Treatment of mice with curcumin
(50, 100 or 300mg kg1) resulted in a significant decrease in the
extent and severity of the injury of the large intestine as
evidenced by macroscopic damage score (Figure 1) as well as
histopathological assessment (Figure 2c and Table 1). The
observed inflammatory changes of the large intestine were
associated with an increase in weight of the colon and spleen as
well as a significant decrease in body weight as compared to
control mice (Figure 3). In contrast, no significant increase of
the weight was found in the colon and spleen of TNBS-treated
mice, which has been pretreated with 50, 100 or 300mg kg1 of
curcumin. Moreover, treatment with these dosages of curcu-
min also significantly reduced the loss in body weight, which
correlated well with the amelioration of the colonic injury.
However, the altered organ weight and body weight of TNBS-
treated mice were not affected by pretreatment of curcumin
with a dose of 25mgkg1 (Figure 3).
Generation of NO and O2

Since infiltration of leucocytes into the mucosa has been
suggested to contribute significantly to tissue necrosis and
mucosal dysfunction of colitis by generating free radicals and
oxidant molecules, both NO and O2
 were measured. NO was
measured in colonic biopsies, whereas O2
 was measured
in extravasated neutrophils (Figure 4). At 4 days after
TNBS treatment, both NO and O2
 levels were significantly
elevated compared to controls (8.871.0 nmolmg1 tissue
and 5.170.5 nmolmin1 106 cells1 compared to
2.070.3 nmolmg1 and 1.370.2 nmolmin1 106 cells1, re-
spectively; Po0.001). Curcumin pretreatment at dose levels of
50, 100 or 300mg kg1 resulted in marked decrease of the
elevated levels of both NO and O2
 in the colon of TNBS-
treated mice (Po0.01). Pretreatment with 25mg kg1 of
curcumin though did not produce any significant effect on
either NO or O2
 production (Figure 4).
Effect of curcumin on myeloperoxidase and malondialde-
hyde levels in TNBS-induced IBD
Colonic injury by TNBS administration was also characterized
by an increase in myeloperoxidase activity (36.773.3 com-
pared with 8.071.3U g1 tissue in controls), indicative of
Figure 1 Effect of curcumin pretreatment on the macroscopic
damage score of colonic tissues after induction of colitis. Mice were
treated with 0.1ml of TNBS (60mgml1) intracolonically and
assessed at various times (2 – 8 days) after treatment. Colonic
damage was scored on a scale of 0 (normal) to 5 (severe) by two
independent observers. Values are means7s.d. of 10 rats for each
group. Results for the curcumin treatment group were compared
against those for the TNBS-treated group with a two-sided
Wilcoxon’s rank-sum test. *Po0.001 vs TNBS.
Figure 2 Effect of curcumin on colon injury. (a) Mucosal from
control mice did not show any histological modifications, (b) TNBS-
induced mucosal injury (at 4 days) associated with transmural
necrosis and oedema and submucosal infiltration of inflammatory
cells and (c) pretreatment with curcumin prevented the disturbances
in morphology associated with TNBS treatment. Original magnifi-
cation:  500.
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neutrophil infiltration in inflamed tissue (Figure 5a) confirm-
ing the enhanced leucocyte infiltration seen at histological
inspection. In this study, the extent of myeloperoxidase activity
closely paralleled the increase of tissue malondialdehyde
(40.774.1 compared with 9.371.4mMg1 tissue in controls),
indicative of a massive lipid peroxidation (Figure 5b). How-
ever, curcumin pretreatment of TNBS-treated mice at dose
levels of 50, 100 and 300mg kg1 significantly prevented
neutrophil infiltration, as assessed by myeloperoxidase activity
(Po0.01) and also prevented the increased accumulation of
malondialdehyde (Po0.01). Nevertheless, curcumin
(25mg kg1) did not produce any significant change in the
elevated levels of either myeloperoxidase or malondialdehyde
when compared to TNBS-treated mice.
Colonic serine protease activity
Since protease levels are known to be elevated in IBD and thus
may play a role in the extensive tissue damage in IBD, protease
activity in colon tissue was analysed. Colon tissue from control
mice had little inherent protease activity (Figure 6, lane 1),
whereas this was markedly increased in TNBS-treated animals
(lane 2). Significantly elevated levels of specific proteases of
mass of B112, 53 and 20 kDa were obtained from colonic
mucosa of TNBS-induced colitis. Earlier studies on experi-
mental model of IBD using specific inhibitors of various
proteases established that the majority of protease activity
observed on the gelatin zymograms is because of serine
proteases (Hawkins et al., 1997). However, curcumin pretreat-
ment (50mgkg1) greatly reduced the degree of protease
activity in the colon of mice, which had received TNBS to
cause colitis (Figure 6, lane 3). The suppression of serine
protease activity in curcumin-treated mice correlates well with
the attenuation of mucosal injury in TNBS-induced colitis.
Cytokine production in treated mice
To gain an insight into the levels of various cytokines and
iNOS after curcumin treatment on TNBS-induced colitis, we
examined the mRNA expression for a representative Th1
cytokine (e.g. IFN-g), a Th1 inducer (e.g. IL-12), a Th2
cytokine (IL-4) and iNOS, which catalyses the generation of
NO from L-arginine and play a major role in IBD. RT – PCR
analysis of cytokine mRNA levels confirmed that experimental
colitic mice treated with curcumin could reverse an established
Th1 response into a possible Th2 response (Figure 7). Thus,
mucosal cells from mice treated with TNBS contained
significantly increased levels of IFN-g and IL-12 p40 mRNAs
than those from control group representing a dominant
inflammatory Th1 response. However, curcumin pretreatment
resulted in marked suppression of both IFN-g and IL-12 p40
mRNA levels with a little induction of IL-4 mRNA in TNBS-
treated mice. In addition, the iNOS mRNA expression, which
was very high in the mucosal cells of TNBS-treated mice, was
significantly decreased by curcumin pretreatment. These
Table 1 Effect of curcumin pretreatment on colonic
cytoprotection following administration of TNBS
Colonic erosion
Scale
0 1 2 3 4 n Mean Pa
Control 6 4 0 0 0 10 0.40
TNBS 0 1 3 3 3 10 2.80
Curcumin (25mgkg1) 0 2 4 2 2 10 2.40 0.4372
Curcumin (50mgkg1) 0 7 2 1 0 10 1.40 0.0052
Curcumin (100mgkg1) 0 7 3 0 0 10 1.30 0.0021
Curcumin (300mgkg1) 0 6 3 1 0 10 1.50 0.0089
Histological scores graded from 0 to 4 as described in
Methods were carried out at 4 days after TNBS administra-
tion. aResults for the curcumin treatment group were
compared against those for the TNBS group with a two-
sided Wilcoxon’s rank-sum test. The histologic scores for
curcumin (50, 100 and 300mgkg1)-pretreated mice were
significantly lower than that of untreated mice with TNBS-
induced colitis (Po0.01).
Figure 3 Effect of curcumin pretreatment on (a) spleen, (b) colon
and (c) body weight. A significant increase in weight was observed at
4 days after TNBS administration in spleen and colon. Curcumin
pretreatment (50, 100 and 300mgkg1) significantly prevented the
loss in body weight (c) as well as reduced the organ weight (a and b).
Values are means7s.d. of 10 rats for each group. *Po0.01 vs
TNBS.
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results suggest that inflammatory Th1 functions have been
effectively suppressed in BALB/c mice by curcumin treatment
so that Th2 functions could possibly be activated to ameliorate
mucosal injury in experimental colitis.
NF-kB in colonic mucosa of treated mice
To determine whether the decreased NO as well as iNOS
mRNA in colonic mucosa was mediated through inhibition of
iNOS transcription by suppression of NF-kB activation, we
performed electophoretic mobility shift assay using nuclear
extracts of whole colonic tissues from control mice (which
received 30% ethanol without TNBS) and curcumin-treated
or- untreated TNBS colitis mice (Figure 8). The administration
of TNBS alone enhanced NF-kB DNA binding activity of
nuclear extracts in the inflamed colonic tissue, which was
suppressed by pretreatment with either 50 or 300mg kg1
curcumin. Excess unlabelled specific oligonucleotides inhibited
NF-kB mobility shift indicating thereby the specificity of
DNA – protein complex.
Discussion
The use of natural anti-inflammatory products provides an
attractive and relatively nontoxic alternative to modulate
inflammatory disorders. Curcumin is an anti-inflammatory
food product that has been used for centuries (Ammon &
Wahl, 1991). However, the lack of information regarding a
mechanism of action for curcumin combined with unknown
effects on mucosal inflammatory gene expression have
precluded the widespread clinical use of curcumin for
treatment of intestinal inflammatory disorders. The present
study has demonstrated that TNBS causes a substantial degree
of inflammation and tissue injury in the mouse colon, which is
Figure 4 Effect of curcumin on NO and O2
 production. (a) NO
production in colonic tissue and (b) O2
 production in neutrophils.
TNBS treatment caused a significant increase of both NO and O2

generation, which were prevented by curcumin pretreatment. Values
are means7s.d. of 10 rats for each group. *Po0.01 vs TNBS.
Figure 5 Effect of curcumin on neutrophil infiltration and lipid
peroxidation. (a) Myeloperoxidase activity and (b) malondialdehyde
levels in the colon. Myeloperoxidase activity and malondialdehyde
levels were significantly increased in TNBS-treated mice in
comparison to control. Curcumin pretreatment showed a significant
reduction of both myeloperoxidase activity and malondialdehyde
levels. Values are means7s.d. of 10 rats for each group. *Po0.01 vs
TNBS.
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associated with an infiltration of the colon with polymorpho-
nuclear cells (histology and myeloperoxidase activity) as well
as lipid peroxidation. The degree of inflammation, tissue injury
and lipid peroxidation caused by TNBS was substantially
reduced in mice treated with a dose of 50mg kg1 curcumin,
which is lower than the maximal tolerated daily dose in
humans (Cheng et al., 2001). The impetus for this natural
product therapy was the earlier observations that apart from
inhibiting the induction of iNOS in macrophages activated
with LPS and IFN-g (Brouet & Ohshima, 1995), oral
administration of curcumin significantly reduced iNOS
mRNA expression in the livers of LPS-injected mice (Chan
et al., 1998). Moreover, the therapy involving curcumin
pretreatment was effective in mice with ongoing disease in
which a proinflammatory Th1 response had been established.
After treatment, the cytokine profile in these mice indicated a
switch from proinflammatory Th1 to anti-inflammatory Th2
pattern.
Reactive NO radical is known to play a central role in
human IBD. Increased production of NO, and the presence of
iNOS protein and iNOS mRNA have been demonstrated in
affected areas of gut in patients suffering from UC or Crohn’s
disease (Rachmilewitz et al., 1995b; Singer et al., 1996; Kimura
et al., 1997). On the other hand, based on data from LPS-
induced inflammation, a concentration-dependent dual effect
in the gut has been suggested (Laszlo & Whittle, 1995). Low
production of NO by cNOS may be protective and inhibitors
of this physiological NOS have been reported to enhance
intestinal lesions in inflammation (Laszlo & Whittle, 1995;
Pfeiffer & Qiu, 1995). Prolonged production of high amounts
of NO by iNOS on the other hand is proinflammatory and
inhibition of iNOS seems to ameliorate the inflammatory
response and tissue injury in experimental colitis (Hogaboam
et al., 1995; McCafferty et al., 1997). An in vivo study by
Figure 6 Protease activity in TNBS-treated animals. (a) TNBS
treatment showed a several-fold increase in protease activity (lane 2)
over the untreated control animals (lane 1). Curcumin-pretreated
mice showed a marked reduction in protease activity (lane 3)
compared to TNBS-treated mice. Numbers on the right indicate
molecular mass in kDa. (b) Band intensities were quantified by
densitometry.
Figure 7 Suppression of Th1 phenotype in TNBS-treated mice
subjected to curcumin pretreatment (50mgkg1) as analysed by
RT – PCR. (a) Expression of IFN-g, IL-12, IL-4, iNOS and b-actin
mRNA by colon tissue samples of control and treated mice. RT –
PCR products were visualized by ethidium bromide staining. RNA
samples were obtained from six mice in each group. Results are
representative of three separate samples. b-actin expression levels
were used as controls for RNA content and integrity. (b) Band
intensities were quantified by densitometry.
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McKenzie et al. (1996) gives direct evidence on NO-induced
injury on gut epithelial cells supporting the detrimental role of
excessive NO in colitis. There is, therefore, good rationale to
suggest that inhibition of excessive NO production by iNOS
inhibitors will serve as promising approach in the management
of IBD. Enhanced NO generation as well as iNOS mRNA
transcripts detected in the inflamed colonic segments may be
attributed to the contribution of macrophages and inflamma-
tory neutrophils since colonic NO generation has also been
found to be stimulated by LPS and IFN-g (Rachmilewitz et al.,
1995a). In contrast to these observations, a deleterious effect of
iNOS deficiency was reported on the ability to resolve a
colonic injury in experimental IBD (McCafferty et al., 1997).
The discrepancy in these reports may relate to the difference in
the stimuli used to induce the injury. However, similar
controversial roles of iNOS-derived NO have been ascribed
in a variety of pathophysiological conditions. Thus, genetic
ablation of iNOS may exert beneficial effects in endotoxic
shock, infection by Toxoplasma gondii and autoimmune
vasculitis (MacMicking et al., 1995; Gilkeson et al., 1997;
Khan et al., 1997), whereas other studies have reported that
deletion of iNOS gene may exacerbate the inflammatory
process in endotoxaemia encephalomyelitis and tuberculosis
(Laubach et al., 1995; MacMicking et al. 1997; Fenyk-Melody
et al., 1998). We provide here the in vivo evidence that
NO concentrations can be downregulated via suppression
of proinflammatory cytokines by curcumin in TNBS-
induced colitis, resulting in a significant amelioration of the
disease.
There is ample evidence in human IBD that the inflamma-
tory cytokines IL-1, TNF and IFN-g are overexpressed and
this finding correlates with reports of excessive amounts of NO
produced by activated iNOS in lamina propria mononuclear
cells and colon epithelial cells (Godkin et al., 1996; Singer et al.,
1996). This prompted us to investigate whether manipulation
of cytokine profile by curcumin would lead to reduced NO
activities and thus decrease mucosal damage. Curcumin
treatment led to a marked suppression in IL-12 mRNA
expression by mucosal cells of TNBS-administered mice,
resulting in a reduced ability to induce IFN-g and perhaps,
an increased ability to induce IL-4 in CD4+ T cells. These
results suggest that curcumin-mediated inhibition of IL-12
production led to the inhibition of Th1 and a possible
enhancement of Th2 cytokine synthesis in CD4+ T cells.
The mechanism by which curcumin inhibits IL-12 production
seems to be through the downregulation of NF-kB -mediated
activation and binding to the p40-kB site, since curcumin is
capable of inhibiting NF-kB activity in electrophoretic
mobility shift assay using nuclear extracts of whole cells of
the colonic tissue. Curcumin has recently been shown to block
cytokine-mediated NF-kB activation and proinflammatory
gene expression by inhibiting inhibitory factor I-kB kinase
activity (Jobin et al., 1999). Since NF-kB activation is believed
to play a major role in the regulation of proinflammatory gene
transcription, therefore, by suppressing it curcumin may
inhibit early steps of inflammation and modulate upregulation
of multiple proinflammatory genes.
It may be mentioned that scavengers of reactive oxygen
including hydrogen peroxide, superoxide anions and hydroxyl
radicals also reduce the tissue injury associated with IBD
suggesting that – in addition to reactive nitrogen, reactive
oxygen species also play an important role in the pathophy-
siology associated with this model of inflammation (Cuzzocrea
et al., 2000). In addition to reactive oxygen, peroxynitrite
(ONOO is also generated in IBD (Zingarelli et al., 1998).
Reactive oxygen and ONOO produce cellular injury and
necrosis via several mechanisms including peroxidation of
membrane lipids, protein denaturation and DNA damage. The
curative effect of curcumin accompanied by reduced levels of
superoxide anions, nitric oxide, malondialdehyde and serine
protease is suggestive of the scavenging capability of both
reactive nitrogen and oxygen species by this beverage product.
These results are consistent with previous data indicating that
curcumin is capable of lowering the generation of both
superoxide and nitric oxide from rat peritoneal macrophages
(Joe & Lokesh, 1994).
Assessment of the physiological relevance of the findings
reported here must take into account the concentrations at
which inhibitory or stimulatory effect of turmeric-derived
polyphenol on cytokine production was observed. Bioavail-
ability of curcumin is low after oral ingestion (Ammon &
Wahl, 1991) but can be sufficiently elevated by coingestion of
piperine in both rats and humans (Shoba et al., 1998).
Nevertheless, highest concentration of curcumin, regardless
of piperine use, is found in the caecum after oral ingestion
(Ammon & Wahl, 1991). In addition, luminal curcumin may
have a topical activity on colonic epithelial cells independent of
systemic absorption. All these observations may have rele-
Figure 8 Effect of curcumin pretreatment on NF-kB activation.
NF-kB activity was upregulated in nuclear extracts from TNBS-
induced colonic mucosa and suppressed by curcumin pretreatment.
Nuclear extracts of the colonic tissue from control mice (lane 1),
untreated mice with TNBS-induced colitis in absence (lane 2) and
presence of 50 molar excess of unlabelled probe (lane 5) and
curcumin (300 and 50mgkg1) treated mice with TNBS-induced
colitis (lane 3 and 4) were analysed.
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vance on the beneficial effect of oral administration of
curcumin in inflammatory disease of the bowel.
In conclusion, this study demonstrates that the degree of
colitis caused by administration of TNBS is significantly
attenuated by turmeric-derived radical scavenger curcumin.
The anti-inflammatory effects of curcumin are associated with
a reduction in (i) upregulation of proinflammatory Th1
cytokine response leading to the suppression of iNOS and
attenuation of the recruitment of neutrophils, (ii) lipid
peroxidation and (iii) ultimately tissue injury. Being a
relatively nontoxic natural product, combined with its
excellent anti-inflammatory activity, curcumin could be useful
in IBD and other conditions associated with local or systemic
inflammation.
This work was supported by grants from Council of Scientific and
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tion, India. The authors thank Maj. Gen. (Dr) S.R. Bhattacharya for
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Note added in Proof: While this paper was under editorial
review, another study of curcumin in experimental colitis in
mice, by Sugimoto et al. was published (Gastroenterology
(2002) 123 1912 – 1922), with similar results to those reported
here.
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